Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Activated Cell Therapy, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Activated Cell Therapy, Inc.: Receives 510(k) clearance from FDA for its "patented cell processing devices used for cell isolation and enrichment," the Mountain View, California firm announces. Consisting of a series of buoyant density solutions and centrifugal devices, ACT's technology "allows the efficient recovery and preparation of important cells, such as stem cells and dendritic cells, from peripheral blood, bone marrow, or cord blood." ACT has clinical studies ongoing to treat patients with breast cancer, leukemia and lymphoma using stem cells from bone marrow and peripheral blood...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006628

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel